Dutch take the lead on biosimilar switching - will others follow?
This article was originally published in SRA
Executive Summary
As evidence accumulates on the use of biosimilars in the real-world setting, it looks as if regulatory agencies in Europe may be softening their stance on interchangeability after the Medicines Evaluation Board in the Netherlands came out in favor of allowing patients taking one biotherapeutic product to be switched to another, including a biosimilar1.